Cargando…

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation

Introduction: Parathyroid carcinoma (PC) is a rare malignancy with a high rate of recurrence and metastasis. Case: A 63-year-old man with a 13-year history of recurrent PC requiring 5 operations, including parathyroidectomies, thyroidectomy, and neck dissections presented with polyuria, polydipsia,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, Niyoti, Dima, Danai, Kuri, Danica Maria Vodopivec, McAneny, David, Kulke, Matthew, Lee, Stephanie L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Tumor Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265680/ http://dx.doi.org/10.1210/jendso/bvab048.2062

Ejemplares similares

MGMT Promoter Methylation and Parathyroid Carcinoma
por: Storvall, Sara, et al.
Publicado: (2019)

A Case of Paraneoplastic Hypoglycemia From Squamous Cell Carcinoma of Undetermined Primary
por: Murati, Jonila, et al.
Publicado: (2021)

A Subtype of Papillary Thyroid Carcinoma Bone Metastasis With Excellent Response to RAI-Therapy
por: Vodopivec, Danica M, et al.
Publicado: (2021)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Protein Signatures of Parathyroid Carcinomas Using Proteomic Analyses
por: Kong, Sung Hye, et al.
Publicado: (2021)

THU525 Atypical Presentation Of Parathyroid Carcinoma In The Lungs
por: Nicolas Jacinto, Jorg Jurgen, et al.
Publicado: (2023)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

THU520 Successful Treatment Of Ectopic ACTH From Metastatic Gastrinoma With Temozolomide Monotherapy
por: Syeda, Asma, et al.
Publicado: (2023)

MON-LB060 Atypical Presentation of Parathyroid Carcinoma: Case Report
por: Cano, Raquel, et al.
Publicado: (2019)

SUN-922 An Indolent Recurrent Parathyroid Carcinoma - A Case Report
por: Murthi, Swetha, et al.
Publicado: (2020)

PSUN377 Use of Novel Therapy in Management of Metastatic Parathyroid Cancer
por: Fernandes, Jyotika, et al.
Publicado: (2022)

SUN-932 Successful Response of Temozolomide (TMZ) in two Patients with Metastatic Pheochromocytoma/Paragangliomas (PPGLs)
por: de Almeida, Tobias Skrebsky, et al.
Publicado: (2020)

MON-LB058 Mediastinal Parathyroid Adenoma Presenting as a Neuroendocrine Tumor
por: Diamond, Samantha, et al.
Publicado: (2019)

MON-920 Pediatric Parathyroid Carcinoma Presenting With Acute Progressive Genu Valgum
por: Hu, Tina Y, et al.
Publicado: (2020)

OR05-03 Treatment Of Parathyroid Neoplasia By Pharmacologic cdk4/6 Inhibition
por: Costa-Guda, Jessica, et al.
Publicado: (2023)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)

SUN-934 A Rare Case of Hyperparathyroidism - Parathyroid Carcinoma, Atypical Adenoma, or Both?
por: Krutilova, Petra, et al.
Publicado: (2020)

MON-925 A Wolf in Sheep’s Clothing: Intermittent Hypercalcemia from an Intrathyroidal Parathyroid Carcinoma
por: Trejo, Jonathan, et al.
Publicado: (2020)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

MON-327 A Case of Parathyroid Carcinoma in a Patient with Late Stage Chronic Kidney Disease
por: Frunza-Stefan, Simona, et al.
Publicado: (2019)

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
por: Calegari, M A, et al.
Publicado: (2017)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

MON-319 A Young Woman with Familial Isolated Primary Hyperparathyroidism Due to Parathyroid Adenoma and Atrophic Gastritis
por: Noor, Arish, et al.
Publicado: (2019)

Authors’ Reply: Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link?
por: Charoenngam, Nipith, et al.
Publicado: (2021)

Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19
por: Charoenngam, Nipith, et al.
Publicado: (2021)

RF05 | PSUN364 A Rare Case of Bilateral Parathyroid Carcinoma in the Setting of Multiple Endocrine Neoplasia Type 1
por: Kesavan Chary, Priyanka, et al.
Publicado: (2022)

THU489 The Role Of Noncoding Genes With The Bidirectional Promoter In Triple-negative Breast Cancer
por: Yang, Barbara, et al.
Publicado: (2023)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
por: Struve, Nina, et al.
Publicado: (2020)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2021)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023)

Congratulatory Message
por: McAneny, Barbara L.
Publicado: (2018)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5u19tq864sk2s9fvnfs8d8tlh5